Key points are not available for this paper at this time.
“Given the large amount of overlapping cardiorenal benefits from these medications in this study, a combination of SGLT2 inhibitors and GLP-1 receptor agonist therapy is an important consideration. Because these agents differ with regard to glycemic control, weight loss, and select kidney and card...”
Edmonston et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: